nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.08.2020 | Opinion

Management of Graves’ hyperthyroidism and orbitopathy in time of COVID-19 pandemic

verfasst von: L. Bartalena, L. Chiovato, C. Marcocci, P. Vitti, E. Piantanida, M. L. Tanda

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Excerpt

The Coronavirus disease 2019 (COVID-19) pandemic has prompted reflections and statements on the management of endocrine and metabolic disorders, including diabetes mellitus, obesity, adrenal insufficiency [1, 2], as well as on the way COVID-19 outbreak might affect our daily clinical practice after the pandemic will be over [3]. …

Puig-Domingo M, Marazuela M, Giustina A (2020) COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Eur J Endocrinol 68(1):2–5. https://doi.org/10.1007/s12020-020-02294-5 CrossRef

Isidori AM, Arnaldi G, Boscaro M, Falorni A, Giordano C, Giordano R, Pivonello R, Pofi R, Hasenmajer V, Venneri MA, Sbardella E, Simeoli C, Scaroni C, Lenzi A (2020) COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion in steroid replacement in adrenal insufficiency. J Endocrinol Invest. 2020 April 25 [Online ahead of print] https://doi.org/10.1007/s40618-020-01266-w

Trimarchi F (2020) An invisible hand has guided clinical endocrinology toward an unexpected future. J Endocrinol Invest. 2020 April 20 [Online ahead of print] https://doi.org/10.1007/s40618-020-01256-y

Smith TJ, Hegedus L (2016) Graves’ disease. N Engl J Med 375(16):1552–1565. https://doi.org/10.1056/nejmra1510030 CrossRefPubMed

Masiello E, Veronesi G, Gallo D, Premoli P, Bianconi E, Rosetti S, Cusini C, Sabatino J, Ippolito S, Piantanida E, Tanda ML, Chiovato L, Wiersinga WM, Bartalena L (2018) Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Invest 41(12):1425–1432. https://doi.org/10.1007/s40618-018-0918-9 CrossRefPubMed

Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH (2018) 2018 European Thyroid Association guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J 7(4):167–186. https://doi.org/10.1159/000490384 CrossRefPubMedPubMedCentral

Lillevang-Johansen M, Abrahamsen B, Jorgensen HL, Brix TB, Hegedus L (2017) Excess mortality in treated and untreated hyperthyroidism is related to cumulative periods of low serum TSH. J Clin Endocrinol Metab 102(7):2301–2309. https://doi.org/10.1210/jc.2017-00166 CrossRefPubMed

Okosieme OE, Taylor PN, Evans C, Thayer D, Chai A, Khan D, Draman MS, Tennant B, Green J, Sayers A, French R, Lazarus JH, Premawardhana LD, Dayan CM (2019) Primary therapy of Graves’ disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes Endocrinol 7(4):278–287. https://doi.org/10.1016/s2213-8587(19)30059-2 CrossRefPubMed

Akamizu T (2018) Thyroid storm: a Japanese perspective. Thyroid 28(1):32–40. https://doi.org/10.1089/thy.2017.0243 CrossRefPubMedPubMedCentral

10.

Azizi F, Malbbosbaf R (2019) Safety of long-term antithyroid drug treatment? A systematic review. J Endocrinol Invest 42(11):1273–1283. https://doi.org/10.1007/s40618-019-01054-1 CrossRefPubMed

11.

Bartalena L, Chiovato L, Vitti P (2016) Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any). J Endocrinol Invest 39(10):1105–1114. https://doi.org/10.1007/s40618-016-0505-x CrossRefPubMed

12.

Bukhari S, Khan M, Kumar N, Mohan V (2017) Increased risk for thionamide-induced agranulocytosis in elderly patients: a case presentation and literature review. BMJ Case Rep. https://doi.org/10.1136/bcr-2017-220924 CrossRefPubMedPubMedCentral

13.

Alfadhli E, Gianoukakis AG (2011) Management of severe thyrotoxicosis when the gastrointestinal tract is compromised. Thyroid 21(3):215–220. https://doi.org/10.1089/thy.2010.0159 CrossRefPubMed

14.

Hodak SP, Huang C, Clarke D, Burman KD, Jonklaas J, Janicic-Kharic N (2006) Intravenous methimazole in the treatment of refractory hyperthyroidism. Thyroid 16(7):291–295. https://doi.org/10.1089/thy.2006.16.691 CrossRef

15.

Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM (2016) The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 5(1):9–26. https://doi.org/10.1159/000443828 CrossRefPubMedPubMedCentral

16.

Jespersen S, Nyygard B, Ostergaard Kristensen L (2015) Methylprednisolone pulse treatment of Graves’ ophthalmopathy is not associated with secondary adrenocortical insufficiency. Eur Thyroid J 4(4):222–225. https://doi.org/10.1159/000440834 CrossRefPubMedPubMedCentral

Titel: Management of Graves’ hyperthyroidism and orbitopathy in time of COVID-19 pandemic
verfasst von: L. Bartalena
L. Chiovato
C. Marcocci
P. Vitti
E. Piantanida
M. L. Tanda
Publikationsdatum: 01.08.2020
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 8/2020
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-020-01293-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Management of Graves’ hyperthyroidism and orbitopathy in time of COVID-19 pandemic

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2020

A COVID-19 pneumonia case report of autoimmune polyendocrine syndrome type 1 in Lombardy, Italy: letter to the editor

Metabolomics and inflammation in polycystic ovary syndrome

A goitrous model for Bartolomeo Vivarini (1432–1499)

Endocrine complications of COVID-19: what happens to the thyroid and adrenal glands?

SARS-CoV-2: a potential trigger for subacute thyroiditis? Insights from a case report

5α-Reductase-2 deficiency: is gender assignment recommended in infancy? Two case-reports and review of the literature

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin